Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02961283 · ClinicalTrials.gov registry record · Phase 1
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Asana BioSciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02961283 is a Phase 1 study that was terminated before completion, run by Asana BioSciences. The registered enrollment target is 24 participants.
The verdict
NCT02961283, a Phase 1 study, was terminated before completion, sponsored by Asana BioSciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The study is divided into two parts. The first part of the study will test various doses of ASN003 to find out the highest safe dose to test in three specific groups. The second part of the study will test how well ASN003 can control cancer. Subjects will be enrolled into one of three groups. Group 1: metastatic or recurrent melanoma with documented BRAFV600 mutation (n=20 evaluable patients) Group 2: metastatic colorectal cancer (CRC), or advanced non-small cell lung cancer (NSCLC) with documented BRAFV600 mutation (n=14 evaluable patients) Group 3: advanced solid tumors with documented PI3K pathway alterations (PIK3CA mutation or PTEN loss) (n=14 evaluable patients)
Interventions
- DRUG ASN003 ascending doses
- DRUG ASN003 MTD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-10 |
| Est. Completion | 2019-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02961283
The ClinicalTrials.gov registry entry for NCT02961283 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Asana BioSciences, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ASN003 ascending doses is the first listed.
NCT02961283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02961283 about?
NCT02961283 is a clinical study titled "Study of ASN003 in Subjects With Advanced Solid Tumors". The study is divided into two parts. The first part of the study will test various doses of ASN003 to find out the highest safe dose to test in three specific groups. The second part of the study will test how well ASN003 can control cancer. Subjects will be enrolled into one of three groups. Grou...
What is the current status of trial NCT02961283?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2016-10. Estimated completion is 2019-02.
What interventions are being tested in trial NCT02961283?
The interventions under investigation include: ASN003 ascending doses (DRUG), ASN003 MTD (DRUG).
Who is sponsoring clinical trial NCT02961283?
This trial is sponsored by Asana BioSciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.